CEL-SCI (FRA:LSR) 3-1 Month Momentum %: -74.04% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSR CEL-SCI Corp FRA:LSR
30 GF Score
Price €1.00
! 2 Warning Signs
View Full Analysis

What is CEL-SCI 3-1 Month Momentum %?

CEL-SCI FRA:LSR 30 3-1 Month Momentum % is -74.04% as of Jul. 20, 2026. GuruFocus rates FRA:LSR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, CEL-SCI ranks worse than 98.92% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-20), CEL-SCI's 3-1 Month Momentum % is -74.04%.

The industry rank for CEL-SCI's 3-1 Month Momentum % or its related term are showing as below:

FRA:LSR's 3-1 Month Momentum % is ranked worse than
98.92% of 1386 companies
in the Biotechnology industry
Industry Median: -13.61 vs FRA:LSR: -74.04

CEL-SCI  (FRA:LSR) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

CEL-SCI 3-1 Month Momentum % Related Terms

FRA:LSR vs OTLC, AEON, CLRB: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, CEL-SCI's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where CEL-SCI's 3-1 Month Momentum % falls into.


FRA:LSR
30GF Score
CEL-SCI Corp FRA:LSR
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI  (FRA:LSR) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -74.04% mean?
CEL-SCI (FRA:LSR) has a 3-1 Month Momentum % of -74.04% as of Jul. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CEL-SCI and its competitors. According to the industry distribution chart, CEL-SCI ranks #1371 out of 1386 companies in the Biotechnology industry, placing it in the top 98.9%.
Is CEL-SCI's 3-1 Month Momentum % too high?
CEL-SCI's current 3-1 Month Momentum % is -74.04%. Based on the distribution chart, CEL-SCI ranks #1371 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CEL-SCI has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's 3-1 Month Momentum % compare to OTLC and AEON?
According to the Biotechnology industry distribution chart, CEL-SCI ranks #1371 out of 1386 companies for 3-1 Month Momentum %. This places CEL-SCI in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CEL-SCI and its competitors. CEL-SCI's current 3-1 Month Momentum % is -74.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current 3-1 Month Momentum % of -74.04%. The current 3-1 Month Momentum % is -74.04%. CEL-SCI's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current 3-1 Month Momentum % is -74.04% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
30GF Score

Get the complete analysis for FRA:LSR

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.00
Price